Kimberly Robinson - Director, Pricing and Market Access
Undergraduate degree in Biology from Queen’s University, MSc in epidemiology from Erasmus University in the Netherlands and MBA from McGill
Kimberly Robinson is Director, Pricing and Market Access at PDCI. Kimberly joined PDCI from PharmaKare Consulting, where she was Principal Consultant, with a focus on PMPRB pricing consultation. Prior to founding PharmaKare, Kimberly spent 18 years with Janssen. During her career at Janssen, she gained expertise in all aspects of market access, including HTA strategy development, health economics and outcomes research, government and stakeholder relations and strategic pricing.
Her longest role (2005 – 2012) was as Director, Strategic Pricing where she gained a diverse array of experience with PMPRB. This included taking 2 medicines to PMPRB Hearings, managing dozens of investigations, executing price increase strategies across dozens of DINs, contributing to the consultations leading to the 2010 Guidelines, and sitting on the Rx&D PMPRB Technical Working Group during the development of the DIP methodology and the revised CPI Guideline.
Kimberly has pricing and market access experience in a broad range of therapeutic areas, including: psychiatry, neurology, gastroenterology, endocrinology, rheumatology, oncology, Women’s Health and virology.
At PDCI, Kimberly leads the Pricing Team and focuses on the development and implementation of strategic public and private reimbursement strategies, market access assessments and new policy impact analyses and assessments.
Kimberly holds an undergraduate degree in Biology from Queen’s University, and MSc in epidemiology from Erasmus University in the Netherlands and an MBA from McGill. She is an avid supporter of the Canadian Association for Population Therapeutics (CAPT-ACTP) and currently serves as CAPT-ACTP Past President and Chair of the CAPT-ACTP Partnership Committee.